OBJECTIVES To analyze budget impact of strategies of anemia correction with different stimulators of erythropoiesis in patients with chronic kidney disease (СКD). METHODS  Pharmacoeconomic analysis included cost modelling for a new strategy for patients with CKD and anemia that includes the use of continuous erythropoietin receptor activator (CERA) compared with traditional darbepoetin alfa (as described in ARCTOS study). The model included two stages: 1. Estimation of costs in 18 week correction period (phase 1 study), and 2. estimation of costs and effectiveness within 10 week period (phase 2 study). The costs were evaluated in two groups of 100 people, the first with CERA and the second with darbepoetin alfa. According to ARCTOS study, fewer patients treated with continuous erythropoietin receptor activator (CERA) required transfusion procedures compared with darbepoetin alfa (2.5% and 6.8%, respectively). The drugs in the study were to be administered under medical supervision in a day hospital. The time horizon of the study was 28 weeks RESULTS The costs of a phase 1 was 53 187.21 in CERA group and 104 528.88 RUB in darbepoetin alfa group. The costs were almost identical in the second phase. The costs in darbepoetin alfa group were 2.7 times higher compared with CERA in respect of blood transfusion and 2 times higher in respect of drug administration. The cost of pharmacotherapy in CERA group was significantly lower than in group of darbepoetin alfa. Total costs in CERA group were 1, 7  times lower than those for darbepoetin alfa. CONCLUSIONS The study demonstrates that administration of CERA is the most economically effective strategy for the treatment of patients with chronic kidney disease in Russia. It is associated with considerably lower costs compared to darbepoetin alfa.